全文获取类型
收费全文 | 234篇 |
免费 | 7篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 8篇 |
基础医学 | 39篇 |
口腔科学 | 4篇 |
临床医学 | 12篇 |
内科学 | 64篇 |
皮肤病学 | 2篇 |
神经病学 | 27篇 |
特种医学 | 7篇 |
外科学 | 21篇 |
预防医学 | 11篇 |
眼科学 | 10篇 |
药学 | 13篇 |
肿瘤学 | 23篇 |
出版年
2023年 | 1篇 |
2022年 | 9篇 |
2021年 | 7篇 |
2020年 | 5篇 |
2019年 | 6篇 |
2018年 | 12篇 |
2017年 | 6篇 |
2016年 | 14篇 |
2015年 | 7篇 |
2014年 | 9篇 |
2013年 | 19篇 |
2012年 | 22篇 |
2011年 | 23篇 |
2010年 | 6篇 |
2009年 | 12篇 |
2008年 | 12篇 |
2007年 | 16篇 |
2006年 | 8篇 |
2005年 | 22篇 |
2004年 | 7篇 |
2003年 | 8篇 |
2002年 | 7篇 |
2000年 | 1篇 |
1998年 | 1篇 |
1997年 | 1篇 |
1994年 | 1篇 |
1990年 | 1篇 |
排序方式: 共有243条查询结果,搜索用时 15 毫秒
1.
Nicolas Pallet Eric Thervet Corinne Alberti Violaine Emal-Aglaé Janine Bedrossian Frank Martinez Carine Roy Christophe Legendre 《American journal of transplantation》2005,5(11):2682-2687
Despite recent improvement, significant racial disparities in outcome still persist after renal transplantation among African American patients in the United States. This study evaluated the association of race and ethnicity with allograft outcomes in a French population of 952 Caucasian (Cauc) patients and 140 African European (AE) patients who underwent renal transplantation in our center between 1987 and 2003. Demographic characteristics were similar for the two cohorts other than cause of end-stage renal failure (more hypertension among AE and more polycystic kidney disease among Cauc) and cold ischemia time (significantly longer for AE). Immunosuppressive treatment was comparable between groups. There were no significant differences between AE and Cauc in the incidence of acute rejection (31% vs. 30%). At 5 years post-transplant, patient survival (93% vs. 92%), graft survival (83% in both groups) and graft function (creatinine clearance 48 mL/min vs. 45 mL/min) were also similar among the AE and Cauc patients. We demonstrate that ethnic origin does not affect outcome after renal transplantation in France. Therefore, differences observed in the United States cannot be only related to immunologic or pharmacologic factors. The results of renal transplantation in patients of African origin could be improved with universal immunosuppressive drug coverage. 相似文献
2.
3.
Violaine Planté-Bordeneuve Jared Gollob Sonalee Agarwal Marissa Betts Kyle Fahrbach 《Expert opinion on pharmacotherapy》2019,20(4):473-481
Background: Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) is a progressive, life-threatening disease. Until recently, tafamidis was the only approved pharmacotherapy. Patisiran significantly improved polyneuropathy and quality of life (QoL) in the phase III APOLLO trial. In the absence of direct comparisons, this analysis aimed to evaluate the comparative efficacy of tafamidis and patisiran in hATTR amyloidosis with polyneuropathy.Research design and methods: Randomized controlled trial evidence for tafamidis was identified by systematic literature review. Indirect treatment comparisons were performed using the standard pairwise Bucher method for endpoints used in both APOLLO and the tafamidis Fx-005 trial: change from baseline in Neuropathy Impairment Score-lower limbs (NIS-LL), Norfolk QoL-Diabetic Neuropathy questionnaire (QoL-DN), NIS-LL response, and mBMI vs. placebo. Inter-trial population differences were assessed by sensitivity analysis.Results: The base-case analysis (FAP Stage 1 APOLLO patients vs. intent-to-treat Fx-005 population) suggested patisiran had a greater treatment effect vs. tafamidis for all endpoints, with significant improvements in mean change in NIS-LL (–5.49) and QoL-DN (–13.10) from baseline to Month 18. Similar trends were observed in all sensitivity analyses.Conclusions: In the absence of direct comparisons, this analysis suggests patisiran has a greater treatment effect than tafamidis in patients with hATTR amyloidosis with polyneuropathy. 相似文献
4.
Sersté T Barrau V Ozenne V Vullierme MP Bedossa P Farges O Valla DC Vilgrain V Paradis V Degos F 《Hepatology (Baltimore, Md.)》2012,55(3):800-806
Liver macronodules, ranging from benign to low-grade or high-grade dysplastic nodules (LGDNs/HGDNs) and hepatocellular carcinoma (HCC), may develop during chronic liver diseases (CLDs). Current guidelines were recently updated and the noninvasive criteria for the diagnosis of small HCC are based on a single typical radiological pattern and nonconclusive coincidental findings with two techniques. This study aimed to assess the accuracy and disagreements of noninvasive multiphasic examinations for the diagnosis of HCC and dysplastic nodules (DNs) and the role of biopsy. Seventy-four consecutive patients with CLD with ultrasound-detected 1-2-cm nodules underwent, within 1 month, multiphasic computed tomography (CT), magnetic resonance imaging (MRI), and biopsy of the nodule. Median age was 60 years; 33 patients (45%) had hepatitis C virus, 20 (27%) had hepatitis B virus, and 13 (18%) patients had no cirrhosis. Biopsy revealed 47 HCCs, 6 HGDNs, 1 LGDNs, 1 cholangiocarcinoma, and 1 epithelioid hemangioendothelioma. There were no tumors in the other 18 patients. All patients (31 of 31; 100%) who had conclusive coincidental findings (i.e., arterial enhancement and washout) on both examinations had HCC or HGDN (sensitivity, 57%; specificity, 100%). All patients (51 of 51; 100%) who had conclusive findings on at least one of the two examinations had HCC or HGDN (sensitivity, 96%; specificity, 100%). There was a disagreement regarding imaging findings between CT and MRI in 21 of 74 (28%) patients and no washout on both examinations in 23 of 74 patients (31%). In these 44 patients, liver biopsy provided an initial accurate diagnosis. CONCLUSION: The noninvasive diagnosis of HCC or HGDN can be obtained if arterial enhancement and washout are found in a single dynamic imaging examination. These findings are frequently discordant on both CT and MRI, supporting the place of biopsy for the diagnosis of small HCCs. 相似文献
5.
Caroline Jouan Violaine Emonard Philippe Ruggeri Laurent Debelle Nadine Hincourt Sophie Lorquet 《Gynecological endocrinology》2016,32(10):807-810
The optimal method to prepare endometrium before frozen embryo transfer (FET) is not yet established. We retrospectively studied 4496 FET and detailed pregnancy and miscarriage rates in three groups of patients according to the endometrium preparation they have followed before their successive FET: clomifene citrate (CC, group 1), artificial cycle (AC, group 2) or switch between CC and AC (group 3). The overall pregnancy rates per transfer were 24.3, 20.8 and 17.3% while the miscarriage rates reached 23.2, 29.8 and 42.5%, respectively. Group 1 experienced the highest ongoing pregnancy rate (18.6%), the lowest being observed in group 3 (10.0%, p?0.001). Here we propose several alternatives to improve our AC protocol (group 2) that seemed less effective than CC (group 1) and we consider the use of a gonadotrophin-stimulated treatment for patients with the lowest reproductive outcomes (group 3). 相似文献
6.
Ferry M Cahouët V Martin L 《Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale》2007,180(1):49-57
While research to date has been successful in quantifying postural behaviour, this paper examines the causes of transition
between postural coordination mode using dynamical variables and, by inference, efficient control strategies underlying postural
behaviour. To this end, six subjects in bipedal stance were instructed to maintain a constant distance between their head
and a visual target that oscillated along the line of sight. Within sessions, participants were exposed to gradual changes
in increasing target motion frequency. Kinematic results showed a sudden transition between in-phase and anti-phase postural
coordination modes in visual target tracking. The dynamical analysis pointed out that (1) the center of pressure (CoP) position
parameter is a crucial parameter in the determination of the adopted coordination mode, (2) the change occurred in response
to limits bordered by the system: the interaction between equilibrium constraints (A/P displacements of CoP), physiological
limits (net joint moments) support the emergence of different postural behaviours and, (3) finally, the anti-phase mode presents
a better distribution of muscular moment between hip and ankle joints and is more effective to achieve high frequency oscillations
with limited CoP displacements. 相似文献
7.
8.
Giampaolo Merlini Violaine Planté-Bordeneuve Daniel P. Judge Hartmut Schmidt Laura Obici Stefano Perlini Jeff Packman Tara Tripp Donna R. Grogan 《Journal of cardiovascular translational research》2013,6(6):1011-1020
This phase II, open-label, single-treatment arm study evaluated the pharmacodynamics, efficacy, and safety of tafamidis in patients with non-Val30Met transthyretin (TTR) amyloidosis. Twenty-one patients with eight different non-Val30Met mutations received 20 mg QD of tafamidis meglumine for 12 months. The primary outcome, TTR stabilization at Week 6, was achieved in 18 (94.7 %) of 19 patients with evaluable data. TTR was stabilized in 100 % of patients with non-missing data at Months 6 (n?=?18) and 12 (n?=?17). Exploratory efficacy measures demonstrated some worsening of neurological function. However, health-related quality of life, cardiac biomarker N-terminal pro-hormone brain natriuretic peptide, echocardiographic parameters, and modified body mass index did not demonstrate clinically relevant worsening during the 12 months of treatment. Tafamidis was well tolerated. In conclusion, our findings suggest that tafamidis 20 mg QD effectively stabilized TTR associated with several non-Val30Met variants. 相似文献
9.
Obada T Alhalabi Michael N C Fletcher Thomas Hielscher Tobias Kessler Tolga Lokumcu Ulrich Baumgartner Elena Wittmann Silja Schlue Mona Gttmann Shaman Rahman Ling Hai Lea Hansen-Palmus Laura Puccio Ichiro Nakano Christel Herold-Mende Bryan W Day Wolfgang Wick Felix Sahm Emma Phillips Violaine Goidts 《Neuro-oncology》2022,24(1):39
BackgroundGlioblastoma is the most common primary malignancy of the central nervous system with a dismal prognosis. Genomic signatures classify isocitrate dehydrogenase 1 (IDH)-wildtype glioblastoma into three subtypes: proneural, mesenchymal, and classical. Dasatinib, an inhibitor of proto-oncogene kinase Src (SRC), is one of many therapeutics which, despite promising preclinical results, have failed to improve overall survival in glioblastoma patients in clinical trials. We examined whether glioblastoma subtypes differ in their response to dasatinib and could hence be evaluated for patient enrichment strategies in clinical trials.MethodsWe carried out in silico analyses on glioblastoma gene expression (TCGA) and single-cell RNA-Seq data. In addition, in vitro experiments using glioblastoma stem-like cells (GSCs) derived from primary patient tumors were performed, with complementary gene expression profiling and immunohistochemistry analysis of tumor samples.ResultsPatients with the mesenchymal subtype of glioblastoma showed higher SRC pathway activation based on gene expression profiling. Accordingly, mesenchymal GSCs were more sensitive to SRC inhibition by dasatinib compared to proneural and classical GSCs. Notably, SRC phosphorylation status did not predict response to dasatinib treatment. Furthermore, serpin peptidase inhibitor clade H member 1 (SERPINH1), a collagen-related heat-shock protein associated with cancer progression, was shown to correlate with dasatinib response and with the mesenchymal subtype.ConclusionThis work highlights further molecular-based patient selection strategies in clinical trials and suggests the mesenchymal subtype as well as SERPINH1 to be associated with response to dasatinib. Our findings indicate that stratification based on gene expression subtyping should be considered in future dasatinib trials. 相似文献